Thoracic Research and Practice
Original Article

PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment

1.

Ege University School of Medicine, Tulay Aktas Oncology Hospital, İzmir, Turkey

2.

Department of Pathology, Ege University School of Medicine, İzmir, Turkey

3.

Department Radiology, Ege University School of Medicine, İzmir, Turkey

Thorac Res Pract 2022; 23: 45-51
DOI: 10.5152/TurkThoracJ.2021.21151
Read: 896 Downloads: 231 Published: 01 January 2022

OBJECTIVE: To show the effect of programmed cell death protein-1ligand (PDL-1) level on survival times in patients with metastatic non-small cell lung cancer (mNSCLC) receiving chemotherapy, to determine the relationship between PDL-1 level, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).

MATERIAL AND METHODS: The data of 158 patients who received chemotherapy for mNSCLC were evaluated retrospectively. Clinical and demographic data, PDL-1 expression levels and follow-up periods of the patients were recorded. The patients were divided into 2 groups according to PDL-1 levels. 

RESULTS: In all patients, progression free survival (PFS) was 5.6 months and overall survival (OS) was 18.8 months. Patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.038). In the gemcitabine and taxane groups, patients with low PDL-1 had a longer PFS than patients with high PDL-1 (p:0.047). There was a significant correlation between NLR and PDL-1 levels. In the groups with high PDL-1, patients with low NLR levels had higher OS than patients with high NLR level (p:0.043). Also, there was a significant difference between the OS patients with low and high PLR levels (p:0.520).

CONCLUSION: In patients with mNSCLC whose PDL-1 levels and NLR levels are low, immunogenic chemotherapies such as gemcitabine and taxane can be tried as an alternative treatment. 

Cite this article as: Gürsoy P, Çakar B, Günenç D, Nart D, Çinkooğlu A, Katgı N. PDL-1 expression and survival in metastatic non-small cell lung cancer patients who received chemotherapy as first-line treatment. Turk Thorac J. 2022;23(1):45-51.

Files
EISSN 2979-9139